Combined radiation therapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer: results of a phase Ii trial
Boven, E.; Tierie, A.H.; Stam, J.; Pinedo, H.M.
Seminars in Oncology 15(6 Suppl 7: 18-19
1988
ISSN/ISBN: 0093-7754 PMID: 2851171 Document Number: 323265
The Free University Hospital in Amsterdam conducted a phase II trial on inoperable patients with non-small cell lung cancer (NSCLC) to evaluate the role of cisplatin as a radiosensitizer. Forty patients were entered into the study. Thirty-three patients were evaluable for response and 37 for toxicity. The regimen consisted of the daily administration of cisplatin 6 mg/m2 administered within 30 minutes after each radiation therapy session. The radiation therapy modality was a regimen of 300 cGy four times per week for 4 weeks with a 2-week split in between, administering a total dose of 48 Gy. The overall response rate was 65%; median duration of control of local disease was 7 months, and overall survival was 10.5 months. Toxicity was considered to be mild. The results appear similar to data using radiation therapy alone; however, the optimum dosing and timing of this combination therapy has not been determined and deserves further clinical studies.